How to Ensure Compliance with EMA & FDA Literature Requirements

In the highly regulated world of pharmacovigilance, compliance with global health authority requirements is non-negotiable. Among the most scrutinized areas during inspections is literature monitoring. Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) expect marketing authorization holders to conduct systematic, ongoing surveillance of scientific and medical literature to identify adverse events and emerging safety signals.

As publication volumes grow and regulatory expectations become more explicit, ensuring compliance has become increasingly complex. Traditional manual approaches are often stretched thin, making it difficult to maintain consistency, timeliness, and documentation quality. This is where intelligent automation platforms such as Tesserblu are helping pharmacovigilance teams modernize their literature workflows while staying fully aligned with EMA and FDA requirements.

In this blog, we will explore what regulators expect, the common compliance pitfalls organizations face, and how leveraging AI-driven solutions from Tesserblu can support a robust, inspection-ready literature surveillance process.

Understanding EMA & FDA Expectations for Literature Monitoring

Both the EMA and FDA require marketing authorization holders to perform regular and systematic reviews of the worldwide scientific literature for potential adverse event reports. These expectations are embedded in Good Pharmacovigilance Practices (GVP) in Europe and FDA post-marketing safety regulations in the United States.

At a high level, regulators expect organizations to establish documented search strategies, define appropriate data sources, conduct screening at defined intervals, and ensure that reportable cases are processed within required timelines. Literature-derived adverse events must be entered into safety systems and submitted to regulatory authorities in accordance with expedited reporting obligations.

In Europe, specific obligations may include monitoring publications listed in EMA medical literature monitoring (MLM) services, as well as conducting additional searches relevant to a company’s product portfolio. In the U.S., FDA expectations emphasize prompt review and reporting of serious and unexpected adverse experiences found in the literature.

Compliance is therefore not limited to conducting searches. It encompasses documentation, traceability, justification of screening decisions, and proof that processes are consistently executed.

The Growing Complexity of Global Literature Surveillance

Meeting EMA and FDA literature requirements would be straightforward if publication volumes were stable and limited. However, the scientific landscape has transformed dramatically. Thousands of journals publish new content daily, and safety-relevant information can emerge from diverse sources including regional journals, online databases, conference proceedings, and open-access platforms.

For global organizations, literature monitoring must cover multiple languages and regions. A safety signal identified in a local journal could have global regulatory implications. Manual review processes, once manageable, now struggle to keep pace with volume and diversity.

In this environment, compliance risk increases. Backlogs may form, screening decisions may become inconsistent, and documentation may become fragmented. During inspections, regulators often focus on these gaps, seeking evidence of systematic control.

To remain compliant, organizations must move beyond reactive processes and adopt scalable, standardized solutions.

Common Compliance Gaps in Literature Monitoring

Despite best intentions, several recurring challenges affect organizations attempting to meet EMA and FDA requirements.

One common issue is inconsistent screening documentation. Regulators expect clear records showing why articles were deemed relevant or irrelevant. When decisions are documented informally or across disparate systems, audit trails become difficult to reconstruct.

Another challenge is timeliness. Literature-derived cases must be processed within strict reporting timelines. If screening backlogs delay identification of reportable events, organizations risk non-compliance.

Search strategy validation is also frequently scrutinized. Authorities may ask how keywords were selected, how frequently searches are updated, and whether all relevant sources are covered. Without structured governance, maintaining updated search strategies becomes difficult.

These gaps are not always due to negligence. They often arise from operational strain and manual limitations. Technology can provide a sustainable solution.

The Role of Automation in Strengthening Compliance

Automation, particularly when powered by artificial intelligence, offers a way to reinforce control and consistency in literature monitoring.

AI-driven systems can screen high volumes of literature quickly, reducing backlog risk. Natural language processing enables contextual analysis of text, improving the identification of relevant safety information. Automated workflows ensure that screening, documentation, and case processing follow standardized pathways.

Importantly, automation enhances traceability. Every screening action, decision timestamp, and reviewer validation can be recorded within a centralized system. This level of documentation provides compelling evidence during inspections that processes are controlled and consistently executed.

However, not all automation is equal. Solutions must be specifically designed for pharmacovigilance compliance rather than generic text analytics. This is where Tesserblu differentiates itself.

How Tesserblu Supports EMA & FDA Compliance

Tesserblu has developed AI-driven pharmacovigilance solutions that directly address the complexities of literature surveillance. Its platform integrates intelligent screening, contextual NLP, workflow automation, and audit-ready documentation into a cohesive system.

By applying natural language processing to abstracts and full-text articles, Tesserblu’s platform interprets semantic meaning rather than relying solely on keyword matches. This reduces false positives while ensuring relevant content is flagged promptly. Faster and more precise identification of potential cases supports compliance with expedited reporting timelines.

Tesserblu also enhances documentation and traceability. Every screening decision is captured within a structured workflow, creating a transparent audit trail. During EMA or FDA inspections, organizations can demonstrate consistent application of screening criteria, timely review processes, and clear documentation of decision rationales.

Furthermore, Tesserblu supports configurable workflows aligned with regional regulatory requirements. Whether addressing European GVP obligations or FDA post-marketing expectations, organizations can tailor processes within the system to meet specific compliance needs.

Ensuring Timely Case Identification and Reporting

One of the most critical compliance aspects is the timely identification and submission of literature-derived adverse events. Delays in screening can cascade into reporting delays.

Continuous monitoring capabilities within Tesserblu’s platform allow organizations to screen new publications as they become available, rather than relying on periodic batch reviews. Automated alerts prioritize high-relevance articles, enabling safety teams to act quickly.

This proactive model aligns with regulatory expectations for prompt reporting. It also reduces the stress associated with deadline-driven batch processing.

By integrating screening outputs directly into downstream case management workflows, Tesserblu further reduces manual handoffs and potential delays.

Strengthening Search Strategy Governance

EMA and FDA inspectors often evaluate how search strategies are developed and maintained. Organizations must demonstrate that search terms are appropriate, comprehensive, and periodically reviewed.

Tesserblu supports governance by providing centralized configuration and documentation of search parameters. Updates to strategies can be tracked, version-controlled, and justified within the system. This structured approach simplifies inspection responses and strengthens process transparency.

Additionally, AI-driven analytics can provide insights into search performance, helping organizations refine strategies over time without compromising coverage.

Multilingual Surveillance and Global Compliance

Given the global nature of literature, compliance requires monitoring beyond English-language publications. Tesserblu’s multilingual capabilities enable contextual analysis across diverse languages, ensuring consistent screening standards worldwide.

This global reach supports compliance with both EMA and FDA expectations, as relevant literature from any geography must be considered if it pertains to marketed products.

By embedding multilingual intelligence into the surveillance process, Tesserblu helps eliminate regional blind spots.

Inspection Readiness as a Continuous State

Regulatory inspections can occur with little notice. Organizations must therefore operate in a constant state of readiness.

Tesserblu contributes to inspection preparedness by generating structured audit trails, maintaining consistent documentation, and enabling real-time performance monitoring. Instead of scrambling to compile evidence before an inspection, safety teams can rely on built-in system documentation.

This continuous readiness reduces compliance anxiety and strengthens organizational confidence during regulatory interactions.

Balancing Innovation and Regulatory Accountability

While automation provides efficiency gains, regulatory compliance requires validation and oversight. Tesserblu’s approach emphasizes human-in-the-loop review, ensuring that AI-generated recommendations are validated by qualified professionals.

This balance between technology and expertise maintains accountability while leveraging automation’s strengths. It reflects a compliance-first mindset, essential when navigating EMA and FDA expectations.

Conclusion: Building Compliance Confidence with Tesserblu

Ensuring compliance with EMA and FDA literature requirements is a complex and evolving challenge. Increasing publication volumes, multilingual sources, and strict reporting timelines place significant pressure on pharmacovigilance teams.

Manual processes alone are no longer sufficient to guarantee consistency, scalability, and documentation quality. Intelligent automation, when thoughtfully implemented, provides the control and efficiency required in today’s regulatory environment.

With its AI-driven screening, contextual NLP, integrated workflows, and audit-ready documentation, Tesserblu empowers organizations to meet and exceed EMA and FDA expectations. By transforming literature monitoring into a streamlined, transparent, and continuously controlled process, Tesserblu helps safety teams stay compliant, inspection-ready, and focused on what matters most — protecting patient safety worldwide. Book a meeting if you are interested to discuss more.